Iovance Biotherapeutics, Inc. (IOVA): Company Future Sales Volume

Graphic logo of Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics (IOVA), a leader in FDA-approved TIL therapy, is attracting top specialists with ambitious stock options, while the GURU.Markets interface displays the company's projected sales dynamics, where 0.38 reflects the latest metric value. However, geopolitics are complicating global trials and biomaterial logistics, and the costs of implementing Amtagvi and scaling production are putting serious pressure on business margins.

Company Revenue Forecast: Iovance Biotherapeutics (IOVA) for 07/04/2022 - 11/17/2026

IOVA (Iovance Biotherapeutics): analytical breakdowns and indicator data

- stock value and consensus price forecast:
- stock exchange capitalization data:
Summary company analysis:Iovance Biotherapeutics, Inc.
Product sample of Iovance Corp

This indicator measures the dynamics of expected operating income, allowing for the identification of speculative overheating of the asset by analyzing the speed of revenue reaction to external shocks. By assessing the sales volume potential of Iovance Biotherapeutics (IOVA) on the GURU.Markets platform, investors determine the entry point, which is critically important for Iovance Biotherapeutics (IOVA) given US intellectual property protections and the absence of geopolitical risks in cancer therapy development.

Direct competitors

Company Projected Revenue ImmunityBio Inc (IBRX)|Company Future Sales Volume Immunocore PLC IMCR|Janux Therapeutics Inc - Company Future Sales Volume|Projected Sales Volume Arcus Corp RCUS|ZYME - Company Projected Revenue|TNGX (tangotx.com) - Company Revenue Forecast|Immatics Biotechnologies (IMTX) - Company Projected Revenue|Company Expected Sales Volume Xencor Corp (XNCR)|Company Future Sales Volume CMPX|REPL - Company Sales Forecast|Company Future Sales Volume LYEL (Lyell Immunopharma Inc)|Company Projected Revenue Volume IPHA|Projected Sales Volume PYXS (Pyxis Oncology, Inc.)|Company Future Revenue CGEN|iobiotech.com - Projected Sales Volume|Company Expected Sales Volume Sutro Biopharma, Inc|MiNK Therapeutics, Inc. (INKT) - Company Projected Revenue|Werewolf Therapeutics Inc. - Company Future Revenue|IMMX (Immix) - Projected Sales Volume|Projected Sales Volume ALX Oncology Holdings Inc.|Company Future Sales Volume CUE (Cue Biopharma Inc.)|PDSB: Company Expected Revenue|Sonnet BioTherapeutics Holdings - Company Future Sales Volume|MAIABiotech.com (MAIA) - Company Expected Sales Volume|LIMN - Company Projected Revenue|LVTX: Company Projected Revenue|NXTC: Projected Sales Volume|Company Expected Sales Volume Leap Therapeutics Inc (LPTX)|Company Future Sales Volume INTS|Company Revenue Forecast SNSE (senseibio.com)|Company Projected Revenue Theriva Biologics (TOVX)|Company Projected Revenue Volume GRTS|Kineta Bio - Company Future Sales Volume|NEXI - Company Future Sales Volume|TSBX: Company Future Sales Volume|VCNX (Vaccinex, Inc.) - Company Revenue Forecast|Harpoon Tx (HARP) - Company Projected Revenue